GLP-1 telehealth oversight and rare disease

On 23 July 2026 STAT News published a podcast episode that put two very different GLP-1-adjacent stories side by side. The first was a reported investigation into the clinical pace at LifeMD, a U.S. telehealth company that markets semaglutide and tirzepatide prescriptions to patients across all 50 states^[1]. The second was a feature on Matt Wilsey, a father who has spent years trying to build a therapy for the ultra-rare childhood cancer caused by the PGBD5 gene^[1]. The two stories sit in different corners of medicine, but they share an underlying question: what does it cost when the medical infrastructure around a drug moves faster than the science?

What the LifeMD investigation reported

LifeMD is a 50-state direct-to-patient telehealth company that Novo Nordisk lists on its own website as a provider offering "legitimate medicine sourcing and patient support" for GLP-1 seekers. The company reported serving over 745,000 patients and prescribes branded GLP-1 medications at price points starting at $149^[1]. STAT's investigation drew on interviews with five former employees and two lawsuits filed by former senior leaders.

Former workers alleged that providers were expected to review approximately 25 patient cases per hour, leaving roughly two minutes per case. Reviews were based on electronic forms completed by patients rather than live clinical conversations. The company was also alleged to have "discouraged providers from asking what they felt were medically relevant questions to patients, so that they don't delay care." LifeMD denied the allegations, describing them as "strenuous" mischaracterisations^[1].

Independent peer-reviewed research on direct-to-consumer GLP-1 telemedicine offers some context. A 2025 study in Digital Health that followed 966 patients prescribed liraglutide through a DTC platform found that 85.6% reported weight loss exceeding 2 kg within 50 days, but 39.8% also experienced adverse events, primarily gastrointestinal. The authors concluded that longer follow-up and "professional evaluation is necessary to confirm long-term safety and efficacy"^[2].

What GLP-1 prescribing via telehealth requires

The EMA authorised semaglutide for weight management under the brand name Wegovy on 6 January 2022, specifying prescription-only status and a requirement for patients to be managed alongside a reduced-calorie diet and increased physical activity^[3]. The label also specifies that treatment should stop if patients do not achieve at least 5% weight loss within 12 weeks. Neither the EMA label nor equivalent FDA-approved labelling contemplates a two-minute asynchronous form review as an adequate prescribing encounter.

The concern raised by clinical observers in the STAT investigation was not that telehealth is inherently unsafe for GLP-1 prescribing, but that speed pressure creates gaps where contraindications and risk factors do not surface. GLP-1 receptor agonists carry a boxed warning on medullary thyroid carcinoma and are contraindicated in patients with multiple endocrine neoplasia type 2. A form-based review that does not reliably surface personal or family history of those conditions represents a clinical gap, not a logistics efficiency.

The Matt Wilsey story: a different kind of urgency

The second story in the podcast has no GLP-1 angle at all. Matt Wilsey is a father who has dedicated years to developing a treatment for a rare childhood cancer driven by the PGBD5 gene. PGBD5, or PiggyBac transposable element derived 5, is an ancient transposase protein that has been repurposed in human development. When it misfires, it creates the DNA rearrangements that drive paediatric solid tumours including medulloblastoma, one of the most common brain cancers in children^[4].

A 2024 study published in Science Advances confirmed that PGBD5 promotes medulloblastoma formation in mouse models and identified its mutation signatures in a cohort of 329 children with the disease^[4]. Research into targeting PGBD5-driven mutagenesis is ongoing, but the science is at an early stage. Wilsey's role, as STAT reported, is that of a parent-turned-advocate who has worked to keep funding and scientific attention directed at a condition affecting a small enough number of children that commercial incentives alone would not sustain it.

What connects these two stories

Both stories sit at the same fault line: the gap between what a drug or therapy can do and what the system built around it actually delivers. The telehealth prescribing story is about infrastructure optimised for volume rather than clinical depth. The rare disease story is about infrastructure that barely exists at all, held together by individual effort because the patient population is too small to generate a commercial return on its own.

For readers tracking the GLP-1 class on this site, the LifeMD story is a reminder that the prescribing encounter matters as much as the pharmacology. A drug with the safety profile of semaglutide or tirzepatide still requires a clinician who has the time and the clinical information to assess whether the prescription is appropriate for that particular patient.

What this is not

This is not evidence that telehealth prescribing of GLP-1 drugs is unsafe by design, or that LifeMD's practices are representative of every telehealth platform in the space. The STAT investigation draws on former employees and lawsuits, which represent one perspective; LifeMD disputes the characterisation. What the reporting does is put a specific set of operational claims on record that deserve scrutiny by regulators, payers, and patients choosing a prescribing service.

The disclaimer that applies to everything on this site applies here too: if you are considering starting a GLP-1 medication, or are already on one and have questions about your care, those questions belong with a clinician who has access to your full medical history, not a two-minute form review.